(Q34390231)

1 August 2017

1 reference

title

Current pharmacotherapy for hepatitis B infection (English)

1 reference

1 August 2017

0 references

M V Galan

1

1 reference

1 August 2017

D Boyce

series ordinal

2

1 reference

1 August 2017

S C Gordon

series ordinal

3

1 reference

1 August 2017

language of work or name

English

0 references

publication date

1 August 2001

1 reference

Expert Opinion on Pharmacotherapy

1 August 2017

published in

1 reference

1 August 2017

volume

2

1 reference

1 August 2017

issue

8

1 reference

1 August 2017

page(s)

1289-1298

1 reference

The infected health care provider

1 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2.8.1289

Recent advances in the molecular biology of hepatitis B virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2.8.1289

The development of cirrhosis in patients with chronic type B hepatitis: A prospective study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2.8.1289

Effect of drinking on the outcome of cirrhosis in patients with hepatitis B or C

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2.8.1289

Clinical and histological features of delta infection in chronic hepatitis B virus carriers

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2.8.1289

The significance of antibody to hepatitis C virus in patients with chronic hepatitis B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2.8.1289

Anti-HBe-positive chronic hepatitis B with HBV-DNA in the serum response to a 6-month course of lymphoblastoid interferon.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2.8.1289

Low-dose, titratable interferon alfa in decompensated liver disease caused by chronic infection with hepatitis B virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2.8.1289

Long-term beneficial effect of interferon therapy in patients with chronic hepatitis B virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2.8.1289

Lamivudine is effective in suppressing hepatitis B virus DNA in Chinese hepatitis B surface antigen carriers: a placebo-controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2.8.1289

Effects of extended lamivudine therapy in Asian patients with chronic hepatitis B. Asia Hepatitis Lamivudine Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2.8.1289

Pretherapy alanine transaminase level as a determinant for hepatitis B e antigen seroconversion during lamivudine therapy in patients with chronic hepatitis B. Asian Hepatitis Lamivudine Trial Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2.8.1289

Hepatitis B virus mutants associated with 3TC and famciclovir administration are replication defective

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2.8.1289

YMDD motif in hepatitis B virus DNA polymerase influences on replication and lamivudine resistance: A study by in vitro full-length viral DNA transfection

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2.8.1289

Acute exacerbation and hepatitis B virus clearance after emergence of YMDD motif mutation during lamivudine therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2.8.1289

Efficacy of long-term lamivudine monotherapy in patients with hepatitis B e antigen-negative chronic hepatitis B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2.8.1289

Acute exacerbation of chronic hepatitis B virus infection after withdrawal of lamivudine therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2.8.1289

Hepatic failure and lactic acidosis due to fialuridine (FIAU), an investigational nucleoside analogue for chronic hepatitis B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2.8.1289

Lamivudine and alpha interferon combination treatment of patients with chronic hepatitis B infection: a randomised trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2.8.1289

Combination therapy with lamivudine and famciclovir for chronic hepatitis B-infected Chinese patients: a viral dynamics study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2.8.1289

Biphasic clearance kinetics of hepatitis B virus from patients during adefovir dipivoxil therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2.8.1289

Mutations in hepatitis B DNA polymerase associated with resistance to lamivudine do not confer resistance to adefovir in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2.8.1289

Adefovir dipivoxil for the treatment of lamivudine-resistant hepatitis B mutants

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2.8.1289

Susceptibility of lamivudine-resistant hepatitis B virus to other reverse transcriptase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2.8.1289

Impact of antivirals and emergence of drug resistance: HSV-2 epidemic control

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2.8.1289

Hepatitis B e antigen seroconversion after lamivudine therapy is not durable in patients with chronic hepatitis B in Korea

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2.8.1289

10.1517/14656566.2.8.1289

21 January 2018

Identifiers

DOI

1 reference

1 August 2017

1 reference